Payment overview · 2025
General Payments
$779.75
37 reported records · 11 companies
Healthcare provider profile · identity verified
Boris Serebryansky, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CEDARHURST, NY · NPI 1275586182
Verified facts
What the public records show
CMS Open Payments records show Boris Serebryansky, MD received $779.75 in general payments during 2025 across 37 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $173.98 | 22.3% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $152.44 | 19.6% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $146.27 | 18.8% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.79 | 8.3% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $58.50 | 7.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.22 | 6.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.04 | 5.3% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $26.46 | 3.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $24.31 | 3.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.19 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.55 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $779.75 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $173.98 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $146.27 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $132.38 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $82.69 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.79 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.79 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $41.04 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $41.04 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.10 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 27 |
| Carvedilol | Carvedilol | 192 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 189 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 184 | 27 |
| Metformin Hcl | Metformin Hcl | 183 | 35 |
| Ezetimibe | Ezetimibe | 174 | 33 |
| Furosemide | Furosemide | 156 | 19 |
| Valsartan | Valsartan | 132 | 25 |
| Losartan Potassium | Losartan Potassium | 128 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 16 |
| Potassium Chloride | Potassium Chloride | 119 | 15 |
| Omeprazole | Omeprazole | 117 | 24 |
| Simvastatin | Simvastatin | 114 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 17 |
| Allopurinol | Allopurinol | 103 | 12 |
| Labetalol Hcl | Labetalol Hcl | 98 | 15 |
| Eliquis | Apixaban | 95 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 19 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 83 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 14 |
| Xarelto | Rivaroxaban | 80 | suppressed |
| Famotidine | Famotidine | 78 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 76 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 76 | 12 |
| Montelukast Sodium | Montelukast Sodium | 75 | 18 |
| Vascepa | Icosapent Ethyl | 69 | suppressed |
| Ranolazine Er | Ranolazine | 67 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 66 | 11 |
| Januvia | Sitagliptin Phosphate | 65 | 11 |
| Benazepril Hcl | Benazepril Hcl | 64 | suppressed |
| Tradjenta | Linagliptin | 62 | suppressed |
| Synthroid | Levothyroxine Sodium | 60 | suppressed |
| Spironolactone | Spironolactone | 59 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 57 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 56 | 21 |
| Irbesartan | Irbesartan | 53 | suppressed |
| Gabapentin | Gabapentin | 52 | 12 |
| Linzess | Linaclotide | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Ozempic | Semaglutide | 50 | suppressed |
| Ramipril | Ramipril | 46 | suppressed |
| Glimepiride | Glimepiride | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 11 |
| Finasteride | Finasteride | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 30 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 12 |
| Felodipine Er | Felodipine | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 12 |
| Praluent Pen | Alirocumab | 24 | suppressed |
| Silodosin | Silodosin | 24 | suppressed |
| Prolia | Denosumab | 23 | 13 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Telmisartan | Telmisartan | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $779.75 · 37 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ACCRUFER, AIRSUPRA, CREON, DUPIXENT, FARXIGA, JARDIANCE, JOURNAVX, LINZESS, MOUNJARO, NUCALA, OTEZLA, REPATHA, TRELEGY ELLIPTA, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error